CalciMedica is a brand that is dedicated to developing CRAC channel inhibitors for acute and chronic inflammatory conditions. Their team is comprised of scientists, physicians, drug development experts, and entrepreneurs who are pioneering therapies for life-threatening inflammatory diseases with high unmet needs. Their executive team is led by Rachel Leheny, Ph.

D., who has over 30 years of experience in the life sciences industry. Kenneth Stauderman, Ph. D., a co-founder and the Chief Scientific Officer, is a leading expert in CRAC channels and has over 30 years of experience in drug discovery and development.

Sudarshan Hebbar, M. D., the Chief Medical Officer, has over 15 years of clinical development and product development experience. CalciMedica offers cutting-edge technologies and a promising pipeline of clinical trials in the fields of pancreas, kidney, and lung.

They are committed to finding innovative solutions for unmet medical needs and improving the lives of patients suffering from inflammatory diseases. With their team of experts, CalciMedica aims to bring effective treatments to those who need them most